Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 9Unknown 4Recruiting 4Withdrawn 3Terminated 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Other hematologic neoplasm 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Colorectal Neoplasms 5Pancreatic Neoplasms 4Breast Neoplasms 4Recurrence 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Ovarian Neoplasms 2Neoplasms, Plasma Cell 2Multiple Myeloma 2Lymphoma 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia 2Esophageal Neoplasms 2Burkitt Lymphoma 2Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Optic Nerve Glioma 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Immunoblastic 1

Interventions

Dexamethasone 14Rituximab 6Cytarabine 5venetoclax 4Lenalidomide 4Bortezomib 4Bendamustine Hydrochloride 4selinexor 3pomalidomide 3pembrolizumab 3ibrutinib 3fludarabine 3carfilzomib 3Paclitaxel 3Gemcitabine 3Drug Therapy 3Cyclophosphamide 3Calcium Dobesilate 3ixazomib 2gilteritinib 2fludarabine phosphate 2elotuzumab 2daratumumab 2belinostat 2Tablets 2Surveys and Questionnaires 2Panobinostat 2Oxaliplatin 2Granulocyte Colony-Stimulating Factor 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Recurrence × Drug Therapy × Clear all
NCT05512182 2023-06-15

Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression

Yonsei University

Phase 2 Withdrawn

Recurrence

NCT00458744 2014-08-08

Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment

Children's Oncology Group

Phase 1 Withdrawn
CNSLymphoidOther hematologic neoplasmSarcoma

Familial ependymoma, Astrocytoma, Burkitt Lymphoma, Leukemia, Lymphoma, Medulloblastoma, Recurrence, Spinal Cord Neoplasms, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Optic Nerve Glioma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Leukemia, Myelomonocytic, Juvenile, Dendritic Cell Sarcoma, Interdigitating

NCT00005969 2012-02-20

Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡